Federal Register / Vol. 72, No.
215 / Wednesday, November 7, 2007 / Notices
investigation is being conducted in an
area where faults serve as both barriers
and conduits for groundwater
movement. Characterization of the
faulted field exposures will include
stratigraphic, lithologic, structural,
hydrologic and geomechanical
investigations. Quantitative deformation
analysis will be performed through a
combination of field- and laboratory-
based analysis.
Membership in this research group
remains open, and the participants
intend to file additional written
notification disclosing all changes in
membership or planned activities.
Patricia A. Brink,
Deputy Director of Operations, Antitrust
Division.
[FR Doc. 07–5566 Filed 11–06–07; 8:45 am]
BILLING CODE 4410–11–M
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Registration
By Notice dated July 31, 2007 and
published in the Federal Register on
August 9, 2007, (72 FR 44858–44859),
Alcan Packaging-Bethlehem, 2400
Baglyos Circle, Bethlehem,
Pennsylvania 18020, made application
by renewal to the Drug Enforcement
Administration (DEA) to be registered as
an importer of Nabilone (7379), a basic
class of controlled substance listed in
schedule II.
The company plans to import the
listed controlled substance for
packaging and distribution.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and 952(a)
and determined that the registration of
Alcan Packaging-Bethlehem to import
the basic class of controlled substance is
consistent with the public interest and
with United States obligations under
international treaties, conventions, or
protocols in effect on May 1, 1971, at
this time. DEA has investigated Alcan
Packaging-Bethlehem to ensure that the
company’s registration is consistent
with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
pwalker on PROD1PC71 with NOTICES
company’s background and history.
Therefore, pursuant to 21 U.S.C. 952(a)
and 958(a), and in accordance with 21
CFR 1301.34, the above named company
is granted registration as an importer of
VerDate Aug<31>2005 16:14 Nov 06, 2007 Jkt 214001
62871
the basic class of controlled substance
listed.
Dated: October 31, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–21859 Filed 11–6–07; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Registration
By Notice dated August 1, 2007 and
published in the Federal Register on
August 9, 2007, (72 FR 44860), Cambrex
North Brunswick, Inc., Technology
Centre of New Jersey, 661 Highway One,
North Brunswick, New Jersey 08902,
made application by renewal to the
Drug Enforcement Administration
(DEA) to be registered as an importer of
Phenylacetone (8501), a basic class of
controlled substance listed in schedule
II.
The company plans to import the
listed controlled substance to
manufacture amphetamine.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and 952(a)
and determined that the registration of
Cambrex North Brunswick, Inc. to
import the basic class of controlled
substance is consistent with the public
interest and with United States
obligations under international treaties,
conventions, or protocols in effect on
May 1, 1971, at this time. DEA has
investigated Cambrex North Brunswick,
Inc. to ensure that the company’s
registration is consistent with the public
interest. The investigation has included
inspection and testing of the company’s
physical security systems, verification
of the company’s compliance with state
and local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 952(a)
and 958(a), and in accordance with 21
CFR 1301.34, the above named company
is granted registration as an importer of
the basic class of controlled substance
listed.
Dated: October 31, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–21865 Filed 11–6–07; 8:45 am]
BILLING CODE 4410–09–P
PO 00000 Frm 00060 Fmt 4703 Sfmt 4703 E:\FR\FM\07NON1.SGM
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on August 22, 2007,
Cayman Chemical Company, 1180 East
Ellsworth Road, Ann Arbor, Michigan
48108, made application by renewal to
the Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of the basic classes of
controlled substances listed in schedule
I:
Drug Schedule
Marihuana (7360) ......................... I
Tetrahydrocannabinols (7370) ..... I
The company plans to manufacture
small quantities of marihuana
derivatives for research purposes. In
reference to drug code 7360
(Marihuana), the company plans to bulk
manufacture cannabidiol. In reference to
drug code 7370
(Tetrahydrocannabinols), the company
will manufacture a synthetic THC. No
other activity for this drug code is
authorized for registration.
Any other such applicant and any
person who is presently registered with
DEA to manufacture such a substance
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections being sent via regular mail
should be addressed, in quintuplicate,
to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), Washington, DC 20537, or any
being sent via express mail should be
sent to Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than January 7, 2008.
Dated: October 31, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–21848 Filed 11–6–07; 8:45 am]
BILLING CODE 4410–09–P
07NON1